Natural history of arteriovenous grafts in hemodialysis patients

医学 低蛋白血症 外科 血液透析 狭窄 血管成形术 血栓形成 内科学
作者
P. Elliott Miller,Donna Carlton,M H Deierhoi,David T. Redden,Michael Allon
出处
期刊:American Journal of Kidney Diseases [Elsevier BV]
卷期号:36 (1): 68-74 被引量:194
标识
DOI:10.1053/ajkd.2000.8269
摘要

Most hemodialysis patients in the United States have an arteriovenous graft as their vascular access. Grafts have a relatively short life span and are prone to recurrent stenosis and thrombosis, requiring multiple salvage procedures to maintain their patency. There is little information in the literature regarding the clinical factors that determine graft survival and complications. We evaluated prospectively the outcomes of 256 grafts placed at a single institution during a 2-year period. A salvage procedure to maintain graft patency (thrombectomy, angioplasty, or surgical revision) was required in 29% of the grafts at 3 months, 52% at 6 months, 77% at 12 months, and 96% at 24 months. Thus, primary graft survival (time from graft placement to the first intervention) was only 23% at 1 year and 4% at 2 years. Primary graft survival was significantly less among patients with hypoalbuminemia compared with patients with a normal serum albumin level (P = 0.003). Secondary graft survival (time from graft placement to permanent graft failure) was 65% at 1 year and 51% at 2 years. Neither primary nor secondary graft survival was significantly correlated with patient age, sex, diabetic status, body mass index, or graft site. A mean of 1.22 interventions per graft-year were required to maintain access patency, including 0.51 thrombectomies, 0.54 angioplasties, and 0.17 surgical revisions. In conclusion, hypoalbuminemia is a strong predictor of the requirement for an early graft intervention. Patients with hypoalbuminemia may require a heightened index of suspicion in monitoring their grafts for evidence of stenosis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
skbkbe完成签到 ,获得积分10
1秒前
受伤毛豆发布了新的文献求助10
1秒前
Yoanna应助元谷雪采纳,获得30
1秒前
爱弹猫的吉他完成签到 ,获得积分10
1秒前
阳光的嫣完成签到,获得积分20
2秒前
3秒前
神秘玩家完成签到 ,获得积分10
3秒前
Vv发布了新的文献求助10
3秒前
4秒前
jiajia发布了新的文献求助10
5秒前
夏沫完成签到,获得积分10
5秒前
6秒前
6秒前
阳光的嫣发布了新的文献求助10
9秒前
9秒前
9秒前
耳机单蹦发布了新的文献求助10
10秒前
隐形曼青应助曲书文采纳,获得10
10秒前
核桃发布了新的文献求助10
13秒前
13秒前
13秒前
14秒前
14秒前
15秒前
传奇3应助lily采纳,获得10
18秒前
20秒前
科研通AI6应助smile采纳,获得10
20秒前
枯藤老柳树完成签到,获得积分10
20秒前
可爱的函函应助Vv采纳,获得10
20秒前
21秒前
21秒前
你好完成签到 ,获得积分10
21秒前
22秒前
hyx9504完成签到,获得积分10
23秒前
24秒前
蓬蓬发布了新的文献求助10
25秒前
LFQ1998发布了新的文献求助10
25秒前
光之剑发布了新的文献求助10
25秒前
hserh完成签到,获得积分10
26秒前
26秒前
高分求助中
Comprehensive Toxicology Fourth Edition 24000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
World Nuclear Fuel Report: Global Scenarios for Demand and Supply Availability 2025-2040 800
Handbook of Social and Emotional Learning 800
Risankizumab Versus Ustekinumab For Patients with Moderate to Severe Crohn's Disease: Results from the Phase 3B SEQUENCE Study 600
Lloyd's Register of Shipping's Approach to the Control of Incidents of Brittle Fracture in Ship Structures 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5134322
求助须知:如何正确求助?哪些是违规求助? 4335087
关于积分的说明 13505951
捐赠科研通 4172482
什么是DOI,文献DOI怎么找? 2287697
邀请新用户注册赠送积分活动 1288658
关于科研通互助平台的介绍 1229444